SynDevRx develops polymer-based drug conjugates for small molecule drug activity.
Syndevrx has raised $29.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2024.
Syndevrx is headquartered in Cambridge, United States.
SynDevRx develops polymer-based drug conjugates for small molecule drug activity.
Syndevrx is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syndevrx — Funding & Investors." VCBacked, October 10, 2024, https://www.vcbacked.co/company/syndevrx. Accessed July 21, 2026.
VCBacked. (2024). Syndevrx — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/syndevrx
{{cite web |title=Syndevrx — Funding & Investors |url=https://www.vcbacked.co/company/syndevrx |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated